Bank Julius Baer & Co. Ltd Zurich Trims Holdings in Haleon PLC Sponsored ADR (NYSE:HLN)

Bank Julius Baer & Co. Ltd Zurich lowered its holdings in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 2.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,691,124 shares of the company's stock after selling 74,740 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.08% of Haleon worth $37,982,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in HLN. Wellington Management Group LLP grew its holdings in shares of Haleon by 67.5% in the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock valued at $146,232,000 after purchasing an additional 6,175,835 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Haleon in the fourth quarter valued at approximately $45,110,000. Raymond James Financial Inc. acquired a new position in shares of Haleon in the fourth quarter valued at approximately $42,193,000. FMR LLC grew its holdings in Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after acquiring an additional 3,909,545 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Haleon by 27.7% during the 4th quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock worth $51,636,000 after acquiring an additional 1,172,931 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wall Street Zen cut shares of Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a report on Friday, May 9th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Finally, BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target for the company in a report on Tuesday, May 27th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $12.33.

Haleon Stock Up 0.2%

Shares of NYSE:HLN traded up $0.02 during trading on Friday, hitting $9.87. 9,878,220 shares of the company were exchanged, compared to its average volume of 12,174,360. The stock has a market capitalization of $44.32 billion, a P/E ratio of 25.30, a PEG ratio of 2.86 and a beta of 0.25. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78. Haleon PLC Sponsored ADR has a 12-month low of $8.86 and a 12-month high of $11.42. The firm's 50 day moving average price is $10.51 and its 200-day moving average price is $10.18.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.